Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inhaled preprandial human insulin with the AERx iMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: A 52-week, open-label, multinational, randomised, parallel trial to investigate long-term safety.

Trial Profile

Inhaled preprandial human insulin with the AERx iMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: A 52-week, open-label, multinational, randomised, parallel trial to investigate long-term safety.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart
  • Indications Diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Oct 2009 Actual initiation date (Aug 2007) added as reported by ClinicalTrials.gov.
    • 24 Jun 2008 The actual end date for this trial is February 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top